Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years
| Condition |
|---|
|
PTSD Post-Traumatic Stress Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Retrospective |
| Official Title: | Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years |
| Estimated Enrollment: | 99 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | September 2005 |
This study is a retrospective electronic review of the VISN 7 Data Warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (PTSD) in the VA
This study is a retrospective electronic review of patients of the VISN 7 Data Warehouse of patients with a diagnosis of PTSD treated with antipsychotics as monotherapy or adjunctive therapy at a VA Medical Center or VA clinic in VISN 7 (GA, SC, and AL). The data will be retrieved from a computerized list of patients treated in VA VISN 7 for PTSD from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. No personal identifiers will be collected. The data will then be examined to determine what type of antipsychotics were prescribed and the dose and duration of the antipsychotics. In addition, demographics and clinical characteristics available through the Data Warehouse will be collected.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female patients, any race or ethnic origin at least 19 years of age.
- Patients with a diagnosis of PTSD
- Treated with an antipsychotic as a monotherapy or adjunctive therapy
- Patient must have been seen at a VA medical center or clinic within VISN 7 during the study period.
Exclusion Criteria:
- Patients not diagnosed with PTSD
- Not treated with an antipsychotic as a monotherapy or adjunctive therapy
- Patients outside of Network 7
- Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
Contacts and Locations| United States, Alabama | |
| Tuscaloosa VA Medical Center | |
| Tuscaloosa, Alabama, United States, 35404 | |
| Principal Investigator: | Lori L. Davis, MD | Tuscaloosa VA Medical Center |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00230893 History of Changes |
| Other Study ID Numbers: | TREAC - PTSD Retrospective, TREAC - PTSD Retrospective |
| Study First Received: | September 29, 2005 |
| Last Updated: | September 20, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Tuscaloosa Research & Education Advancement Corporation:
|
Antipsychotics PTSD Post Traumatic Stress Disorder monotherapy adjunct therapy |
Additional relevant MeSH terms:
|
Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Anxiety Disorders Mental Disorders Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 19, 2013